Tesamorelin (5mg, 10mg)

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH).
It has been studied extensively for reducing visceral adipose tissue (VAT), regulating growth hormone secretion, and supporting metabolic health.

Product Profile

• Compound: Tesamorelin acetate

• Class: GHRH analog peptide

• Form: Lyophilized injectable powder

• Available vial sizes: 5mg and 10mg

• Use: Laboratory and clinical research

Mechanism of Action

• GHRH receptor binding – Stimulates the anterior pituitary to release growth hormone (GH).

• IGF-1 increase – GH upregulation elevates insulin-like growth factor-1, promoting tissue growth and repair.

• Visceral fat reduction – Clinical trials confirm selective loss of VAT without reducing subcutaneous fat.

• Metabolic regulation – Improves lipid metabolism and glucose handling.

Documented Research Outcomes

Visceral Fat Reduction

• Subjects recorded a 15–20% reduction in VAT within 6 months.

• Subcutaneous fat remained stable, confirming selective visceral targeting.

Growth Hormone and IGF-1 Response

• GH pulses were significantly elevated after daily subcutaneous injections.

• IGF-1 levels increased by 100–150 ng/mL above baseline in most studies.

Metabolic Effects

• Improved triglyceride profiles.

• Reduced C-reactive protein, indicating lower systemic inflammation.

Cognitive and Neural Impact

• Some studies document improved memory scores and white matter integrity in older adults.

Comparative Notes: 5mg vs 10mg Vials

• 5mg vial: Common in shorter cycles or titration studies.

• 10mg vial: Used in extended protocols requiring larger cumulative dosing.

Tesamorelin Research FAQs

1. What is Tesamorelin?
Tesamorelin is a GHRH analog designed to stimulate natural growth hormone release.

2. What vial sizes are available?
It is available in 5mg and 10mg lyophilized vials.

3. How does Tesamorelin reduce belly fat?
Clinical trials report a 15–20% VAT reduction over 6 months by elevating GH and IGF-1 activity, which mobilizes stored fat in the abdominal cavity.

4. How is Tesamorelin different from direct GH injections?

• Tesamorelin stimulates the body’s own GH release, preserving physiological pulsatility.

• Direct GH bypasses regulation and can cause non-physiological spikes.

5. What metabolic improvements are associated with Tesamorelin?

• Lower triglycerides

• Reduced inflammatory markers

• Improved glucose handling

6. What is Tesamorelin’s half-life?
The peptide has a plasma half-life of ≈30 minutes, but its biological activity lasts longer due to GH pulse stimulation.

7. How long does it take to observe fat reduction?
Significant VAT decreases are documented within 3–6 months of research cycles.

8. Does Tesamorelin affect muscle growth?
Increased GH and IGF-1 support muscle protein synthesis, but its strongest evidence lies in fat reduction studies.

9. How does Tesamorelin impact cognition?
Research shows improvements in verbal memory and brain structure integrity, especially in older populations.

10. Is Tesamorelin approved for medical use?
Yes. It is FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy, while also being studied in broader metabolic contexts.